Home
About Us
About Boan
Culture
Our History
Our Team
Responsibility
R&D
Technology platform
Boan Product Pipeline
Intellectual Property
Production capacity
Products
News
Careers
People Strategy
Development
Job Opportunities
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Contact us
简
/
繁
/
EN
News
Year
2021
2022
2023
2024
2025
2026
Month
1
2
3
4
5
6
7
8
9
10
11
12
2026.03.31
Boan Biotech Announces 2025 Financial Results
2026.01.09
Boan's Denosumab (60mg) Approved for Market Launch in Bolivia
2025.12.10
Boan Biotech Grants NKF Exclusive Rights to Commercialize Two Denosumab Drugs in the US
26
2025-11
Boan Biotech’s Boyoujing
®
Approved for Marketing in China for the Treatment of nAMD and DME
07
2025-11
Marketing Authorization Applications for Boan Biotech’s Two Denosumab Injections Accepted in the UK
31
2025-10
BA1104 Phase III Trial in China Completes Patient Enrollment
20
2025-10
Boan Biotech Presents Early Findings about BA1301 at ESMO 2025
28
2025-08
Boan Biotech Announces 2025 Half-Year Results
08
2025-08
Boyouping®, China’s First Locally Developed Dulaglutide Injection, Approved for Marketing
15
2025-07
Dr. Changlin Dou Appointed IFPMA ICH M18 Task Force Lead Expert
1
2
3
4
5
Follow me
鲁公网安备37069102000284
ICP备：鲁ICP备2021004064号-1
